Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity

The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients—androgen deprivation therapy (ADT) alone—until metastatic progression is now considered suboptimal. Several randomized phase III clinical tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fernando López-Campos, Antonio Conde-Moreno, Marta Barrado Los Arcos, Antonio Gómez-Caamaño, Raquel García-Gómez, Asunción Hervás Morón
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	nonmetastatic castration-resistant prostate cancer second generation anti-androgens apalutamide enzalutamide darolutamide overall survival Medicine R
Acceso en línea:	https://doaj.org/article/ebbad03a6fdf4b23a5af69a2cb8f690b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ebbad03a6fdf4b23a5af69a2cb8f690b
record_format	dspace
spelling	oai:doaj.org-article:ebbad03a6fdf4b23a5af69a2cb8f690b2021-11-25T18:07:54ZTreatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity10.3390/jpm111111902075-4426https://doaj.org/article/ebbad03a6fdf4b23a5af69a2cb8f690b2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1190https://doaj.org/toc/2075-4426The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients—androgen deprivation therapy (ADT) alone—until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits—including significantly better overall survival (OS)—for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.Fernando López-CamposAntonio Conde-MorenoMarta Barrado Los ArcosAntonio Gómez-CaamañoRaquel García-GómezAsunción Hervás MorónMDPI AGarticlenonmetastatic castration-resistant prostate cancersecond generation anti-androgensapalutamideenzalutamidedarolutamideoverall survivalMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1190, p 1190 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nonmetastatic castration-resistant prostate cancer second generation anti-androgens apalutamide enzalutamide darolutamide overall survival Medicine R
spellingShingle	nonmetastatic castration-resistant prostate cancer second generation anti-androgens apalutamide enzalutamide darolutamide overall survival Medicine R Fernando López-Campos Antonio Conde-Moreno Marta Barrado Los Arcos Antonio Gómez-Caamaño Raquel García-Gómez Asunción Hervás Morón Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
description	The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients—androgen deprivation therapy (ADT) alone—until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits—including significantly better overall survival (OS)—for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.
format	article
author	Fernando López-Campos Antonio Conde-Moreno Marta Barrado Los Arcos Antonio Gómez-Caamaño Raquel García-Gómez Asunción Hervás Morón
author_facet	Fernando López-Campos Antonio Conde-Moreno Marta Barrado Los Arcos Antonio Gómez-Caamaño Raquel García-Gómez Asunción Hervás Morón
author_sort	Fernando López-Campos
title	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
title_short	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
title_full	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
title_fullStr	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
title_full_unstemmed	Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
title_sort	treatment landscape of nonmetastatic castration-resistant prostate cancer: a window of opportunity
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/ebbad03a6fdf4b23a5af69a2cb8f690b
work_keys_str_mv	AT fernandolopezcampos treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity AT antoniocondemoreno treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity AT martabarradolosarcos treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity AT antoniogomezcaamano treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity AT raquelgarciagomez treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity AT asuncionhervasmoron treatmentlandscapeofnonmetastaticcastrationresistantprostatecancerawindowofopportunity
_version_	1718411593402810368

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity

Ejemplares similares